Trend analysis: Synthetic biology for materials & chemicals — where the value pools are (and who captures them)

The global synthetic biology market reached $18.9 billion in 2025 and is projected to exceed $65 billion by 2032, yet fewer than 15% of bio-based materials startups founded between 2015 and 2020 have achieved commercial-scale production, according to a 2025 analysis by McKinsey & Company. This stark contrast between market projections and realized commercial outcomes reveals a sector where enormous value creation potential coexists with concentrated capture by a surprisingly narrow set of players. Understanding where the value pools actually sit, and who is positioned to claim them, is essential for investors, corporate buyers, and innovators navigating the transition from petrochemical to biological manufacturing.

Why It Matters

The chemical industry generates approximately 6% of global greenhouse gas emissions and consumes roughly 10% of global fossil fuels as feedstock, making it the third-largest industrial source of CO2 after cement and steel. Synthetic biology offers a fundamentally different production paradigm: engineering microorganisms, cell-free systems, or enzymatic pathways to convert renewable feedstocks (sugars, waste gases, CO2) into materials and chemicals that currently derive from petroleum. The European Commission's Bioeconomy Strategy targets 25% of chemical production from biological routes by 2035, while the UK's National Bioeconomy Strategy, published in late 2024, commits £2 billion in public investment to scale bio-manufacturing domestically.

The strategic significance extends beyond emissions reduction. Supply chain vulnerabilities exposed during 2020-2024 demonstrated the risks of petrochemical dependence, with feedstock price volatility contributing to margin compression across downstream industries. Bio-based production pathways offer geographic diversification of feedstock sourcing, reduced exposure to oil price shocks, and potential for distributed manufacturing closer to agricultural feedstock sources. For the UK specifically, synthetic biology represents an opportunity to leverage world-class research capabilities at institutions including the Edinburgh Genome Foundry and Imperial College's Centre for Synthetic Biology into commercial leadership.

The regulatory environment is also accelerating adoption. The EU's Corporate Sustainability Reporting Directive (CSRD) requires detailed disclosure of Scope 3 emissions, incentivizing companies to source lower-carbon materials. The UK's Extended Producer Responsibility (EPR) reforms, phasing in through 2026, impose fees calibrated to material recyclability and environmental impact, creating direct financial advantages for bio-based and biodegradable alternatives.

Key Concepts

Precision Fermentation uses genetically engineered microorganisms (typically yeast, bacteria, or fungi) grown in bioreactors to produce specific target molecules. Unlike traditional fermentation that yields bulk products such as ethanol, precision fermentation programs organisms to synthesize high-value compounds including proteins, enzymes, flavours, fragrances, and specialty chemicals. The economics depend heavily on titre (grams of product per litre of culture), productivity (grams per litre per hour), and yield (percentage of feedstock converted to product). Moving from laboratory titres of 1-5 g/L to commercial requirements of 50-150 g/L remains the central scale-up challenge.

Cell-Free Biomanufacturing extracts the cellular machinery (enzymes, ribosomes, cofactors) from organisms and uses it in vitro to perform biosynthesis without living cells. This approach eliminates challenges related to cell viability, metabolic burden, and contamination that plague fermentation, while enabling higher product concentrations and simpler purification. Cell-free systems are particularly suited to toxic products that would kill host organisms, and to rapid prototyping of new pathways. However, enzyme stability and cofactor regeneration costs currently limit applications to high-value targets above $50 per kilogram.

Metabolic Engineering and Directed Evolution represent the core enabling technologies. Metabolic engineering redesigns cellular pathways to maximise flux toward desired products and minimise wasteful side reactions. Directed evolution, recognised by the 2018 Nobel Prize in Chemistry awarded to Frances Arnold, rapidly screens millions of enzyme variants to identify those with improved activity, selectivity, or stability under industrial conditions. Together, these disciplines reduce the time from pathway design to production-ready strain from 5-7 years in the early 2010s to 18-30 months today.

Techno-Economic Analysis (TEA) and Life Cycle Assessment (LCA) are critical decision tools that determine which bio-based products are commercially viable and genuinely lower-carbon. TEA models production costs across feedstock, conversion, and purification stages. LCA quantifies environmental impacts across the full value chain. Products that pass both TEA (cost-competitive with petrochemical alternatives) and LCA (demonstrably lower carbon intensity) screens represent the real value pools. Products that pass only one screen face either commercial failure or greenwashing accusations.

Synthetic Biology Value Pools by Segment

Segment	Market Size 2025	Projected CAGR (2025-2032)	Gross Margins	Key Value Driver
Specialty Chemicals	$4.2B	18-22%	45-65%	Performance differentiation
Bio-based Polymers	$6.8B	12-16%	20-35%	Regulatory premiums
Fragrances & Flavours	$1.9B	22-28%	55-75%	Supply security
Industrial Enzymes	$7.1B	8-12%	40-55%	Process efficiency gains
Bio-surfactants	$2.3B	14-18%	30-45%	Consumer demand for natural
Bio-based Fibres	$1.4B	25-32%	35-50%	Textile sustainability mandates

What's Working

High-Value Specialty Molecules

The clearest value pools sit in products where biology delivers performance advantages impossible to achieve through petrochemistry, not simply cost parity with petroleum incumbents. Amyris, before its 2023 restructuring, demonstrated that farnesene-derived squalane could command price premiums of 3-5x over petrochemical equivalents in cosmetics applications because biological production delivered superior purity and consistency. Ginkgo Bioworks, operating the world's largest organism foundry in Boston, has executed over 150 cell programs for partners across pharma, agriculture, and materials, generating platform licensing revenues exceeding $350 million in 2024. The lesson is clear: value accrues to platforms that can engineer organisms for multiple customers and applications, not to single-product companies competing on cost against established petrochemical incumbents.

Spider Silk and Performance Bio-materials

Bolt Threads, headquartered in Emeryville, California, engineered recombinant spider silk proteins expressed in yeast and commercialised them as Microsilk for luxury fashion applications with Stella McCartney and as Mylo, a mycelium-based leather alternative, with Adidas, Lululemon, and Kering. Although Bolt Threads paused Microsilk production in 2023 to focus on Mylo, the trajectory illustrates a repeatable pattern: bio-materials succeed first in premium segments where sustainability credentials and novel performance properties justify price premiums, then migrate downstream as production costs decline through scale and process optimisation.

Enzyme-Enabled Circular Chemistry

Carbios, based in Clermont-Ferrand, France, developed an enzymatic PET recycling process that depolymerises waste plastic bottles and textiles back to virgin-quality monomers at over 97% conversion efficiency. Their first commercial plant, a joint venture with Indorama Ventures operational in 2025, processes 50,000 tonnes of PET waste annually. The value capture is compelling: Carbios licenses the enzymatic technology while partners invest in capital-intensive plant construction. This asset-light licensing model generates 70-80% gross margins compared to 15-25% for companies that own and operate bio-manufacturing facilities directly.

What's Not Working

Bulk Bio-chemicals at Commodity Prices

Companies targeting direct cost competition with petrochemical commodities have struggled consistently. The history of bio-succinic acid illustrates the challenge: despite technical feasibility demonstrations by BioAmber, Reverdia, and Myriant, none achieved sustainable commercial operations because oil price declines in 2014-2016 and again in 2020 destroyed unit economics calibrated to $80-100 per barrel crude oil. Bio-based 1,4-butanediol and bio-adipic acid have faced similar headwinds. The fundamental problem is that petrochemical plants benefit from 50-70 years of process optimisation and fully depreciated capital, advantages that novel biological processes cannot overcome on cost alone.

Scale-Up Failures and the "Valley of Death"

The transition from 10-litre laboratory fermenters to 200,000-litre commercial bioreactors remains treacherous. Biological processes that perform reliably at bench scale frequently fail at larger volumes due to oxygen transfer limitations, shear stress on cells, temperature gradients, and contamination risks that only manifest in large vessels. A 2025 survey by the Bio-based Industries Joint Undertaking found that 45% of EU-funded bio-manufacturing projects experienced at least 18-month delays in reaching target production volumes, with median cost overruns of 40-60% relative to initial techno-economic projections.

Feedstock Competition and Sustainability Concerns

First-generation bio-based chemicals using food-crop sugars (corn, sugarcane) face increasing scrutiny over land-use competition and indirect emissions. The EU's Renewable Energy Directive III restricts the contribution of crop-based biofuels and, by extension, applies pressure to crop-based bio-chemicals. Companies that fail to transition to second-generation feedstocks (lignocellulosic biomass, waste gases, or CO2) risk losing the sustainability premium that justifies their existence. LanzaTech's gas fermentation platform, converting industrial waste gases to ethanol and other chemicals, represents the direction of travel, but second-generation feedstock conversion costs remain 30-50% higher than sugar-based routes.

Key Players

Established Leaders

Ginkgo Bioworks operates the world's largest biological foundry, offering organism engineering as a service across multiple end markets including materials, food ingredients, and pharmaceuticals. Their horizontal platform model captures value through cell program fees and downstream royalties.

Novozymes (now Novonesis following the 2024 merger with Chr. Hansen) dominates the $7 billion industrial enzyme market with over 48% global share, providing biological catalysts that enable bio-manufacturing across detergents, textiles, food processing, and biofuels.

DSM-Firmenich combines synthetic biology capabilities with deep application expertise in nutrition, fragrances, and materials, leveraging precision fermentation to produce vitamins, flavours, and specialty ingredients at commercial scale.

BASF invested over €400 million in bio-based chemicals R&D between 2020 and 2025, focusing on bio-surfactants, bio-based polyamides, and enzymatic processes integrated into existing petrochemical value chains.

Emerging Startups

Solugen (Houston, Texas) uses chemoenzymatic processes to produce hydrogen peroxide and other commodity chemicals from plant-derived sugars at costs competitive with petrochemical routes, achieving commercial scale with a 10,000 tonne per year facility.

Checkerspot (Berkeley, California) engineers microalgae to produce performance oils for polyurethane foams and coatings, targeting high-margin applications in outdoor gear and automotive interiors.

Constructive Bio (Cambridge, UK) engineers bacteria to synthesise novel polymers with programmable properties, operating from the UK's largest synthetic biology cluster around the Cambridge Biomedical Campus.

Mycorena (Gothenburg, Sweden) produces mycoprotein-based materials through fungal fermentation, targeting both food and materials applications with a vertically integrated production model.

Key Investors and Funders

SOSV and its IndieBio accelerator have funded over 200 synthetic biology startups, representing one of the most active early-stage investors in the sector.

Breakthrough Energy Ventures has deployed significant capital into bio-manufacturing, including investments in Solugen, LanzaTech, and other companies engineering biological production pathways.

UK Research and Innovation (UKRI) channels public investment through the Biotechnology and Biological Sciences Research Council (BBSRC) and Innovate UK, with cumulative synthetic biology funding exceeding £600 million since 2012.

Action Checklist

• Map your organisation's chemical and material inputs by volume, cost, and carbon intensity to identify candidates for bio-based substitution
• Prioritise substitution targets where bio-based alternatives offer performance or regulatory advantages, not just cost parity
• Evaluate potential bio-based suppliers using both techno-economic analysis and life cycle assessment data, rejecting claims unsupported by third-party verification
• Negotiate offtake agreements with bio-based producers that include price escalation clauses tied to feedstock costs and volume-based discounts as production scales
• Engage with industry consortia such as the Bio-based Industries Consortium or the UK BioIndustry Association to track regulatory developments and pre-competitive research
• Assess intellectual property exposure: ensure freedom-to-operate analyses cover engineered organism patents, process patents, and strain access agreements
• Build internal capabilities in bio-material qualification and testing, as bio-based materials may exhibit different processing characteristics than petrochemical equivalents
• Establish feedstock sustainability criteria for bio-based procurement, requiring suppliers to demonstrate compliance with land-use and food security standards

FAQ

Q: Which bio-based materials are closest to cost parity with petrochemical alternatives? A: Industrial enzymes already outperform chemical catalysts on total cost of ownership in many applications, which is why the enzyme market exceeds $7 billion globally. Bio-surfactants are approaching parity in personal care applications, with rhamnolipids from Evonik and sophorolipids from multiple producers priced within 10-20% of petroleum-derived surfactants. Bio-based succinic acid and 1,4-butanediol have achieved technical cost parity at oil prices above $80 per barrel but remain vulnerable to oil price declines. For bulk polymers like bio-PET and bio-PE, cost premiums of 20-40% persist and are unlikely to close without carbon pricing or regulatory mandates.

Q: How should investors evaluate synthetic biology companies differently from traditional chemical companies? A: Focus on three metrics that traditional chemical analysis overlooks. First, strain improvement velocity: how quickly can the company improve titre, rate, and yield? Companies improving these metrics by 2-3x annually are on track; those plateauing after initial gains face commoditisation risk. Second, platform breadth: can the organism engineering capability address multiple products and markets, or is it locked into a single molecule? Platform companies command 3-5x higher revenue multiples. Third, downstream integration: does the company control formulation and customer relationships, or is it selling bulk intermediates into competitive markets?

Q: What regulatory changes will most impact synthetic biology adoption in the UK and EU? A: Three regulatory developments are critical. The EU's proposed revision of REACH regulations may create expedited approval pathways for bio-based chemicals with demonstrated lower toxicity profiles, reducing time-to-market by 12-18 months. The UK's Genetic Technology (Precision Breeding) Act 2023 already streamlines approvals for precision-bred organisms, and extension of similar frameworks to industrial microorganisms is under consultation. The EU's Carbon Border Adjustment Mechanism (CBAM), expanding to cover organic chemicals from 2026, will impose carbon costs on imported petrochemicals, directly improving the competitive position of lower-carbon bio-based alternatives produced domestically.

Q: What are the biggest risks to a synthetic biology investment thesis? A: The three primary risks are feedstock price volatility (sugar prices affect bio-manufacturing costs as directly as oil prices affect petrochemicals), regulatory uncertainty around genetically modified organisms in industrial applications (particularly in the EU, where public acceptance remains fragile), and the persistent challenge of scale-up, where laboratory results fail to translate to commercial production volumes. Investors should also monitor the "platform risk" that foundry models like Ginkgo's face: if customers internalise organism engineering capabilities, the foundry's value proposition diminishes.

Sources

• McKinsey & Company. (2025). The Bio Revolution: Innovations Transforming Economies, Societies, and Our Lives, 2025 Update. New York: McKinsey Global Institute.
• European Commission. (2024). EU Bioeconomy Strategy Progress Report 2024. Brussels: Directorate-General for Research and Innovation.
• UK Government Department for Science, Innovation and Technology. (2024). National Bioeconomy Strategy. London: HMSO.
• SynBioBeta. (2025). Global Synthetic Biology Market Report 2025. Emeryville, CA: SynBioBeta.
• Bio-based Industries Joint Undertaking. (2025). Scale-Up Performance of EU Bio-Manufacturing Projects: Lessons from the First Five Years. Brussels: BBI JU.
• International Energy Agency. (2025). The Chemical Industry in Net Zero Transitions. Paris: IEA Publications.
• UK Research and Innovation. (2025). Synthetic Biology for a Sustainable Future: UKRI Investment Portfolio Analysis. Swindon: UKRI.